Immunology Topic Homepage

Learning Zones

,Lernbereich symptomatisches Asthma

Dieses Fortbildungsmaterial wurde für Gesundheitsexperten in Europa, die mit der Versorgung von Asthma-Patienten betraut sind, entwickelt.

Mehr Bewusstsein für die Krankheit - Dieser Bereich liefert Hintergrundinformationen zu den Auswirkungen des symptomatischen Asthmas und klärt über potenzielle Behandlungsstrategien auf.

RCGP-akkredierte CME - Im Rahmen der Maßnahmen zur kontinuierlichen berufsbegleitenden Fortbildung für Ärzte (CME) können Sie mehr über die Behandlung des symptomatischen Asthmas in der Praxis aus der Perspektive der Ärzte erfahren. In vier Runden erörtern Richard Russell und Thys van der Molen folgende Themen:

  1. Was ist Asthmakontrolle: Wer, warum und wie viele?
  2. Verbesserung der Asthmakontrolle in der Gemeindeversorgung
  3. Derzeitige Standardbehandlung bei Asthma
  4. Pro und Contra zusätzlicher Add-on-Therapien

Wenn Sie den Evaluierungsfragebogen vollständig ausfüllen, wird Ihnen eine Stunde für Ihr CPD-Zertifikat angerechnet.

SPIRIVA® Respimat® ist in der Europäischen Union, Japan, USA und vielen anderen Ländern für die Anwendung bei Asthma zugelassen. Die Indikation ist von Land zu Land verschieden. Dieses Fortbildungsmaterial kann daher Informationen über Medikationen enthalten, für die in Ihrem Land möglicherweise keine Indikationen zugelassen sind.

,Zone d’apprentissage de l’asthme symptomatique

Ces ressources pédagogiques ont été développées pour les professionnels de la santé en Europe, impliqués dans la prise en charge de patients asthmatiques.

Sensibilisation à la maladie – Cette section fournit des informations générales à propos de l’impact de l’asthme symptomatique et de stratégies de prise en charge potentielles.

FMC accréditée par le RCGP – Au sein des activités de Formation Médicale Continue (FMC), vous aurez accès aux perspectives de médecins sur la prise en charge pratique de l’asthme symptomatique. Richard Russell et Thys van der Molen abordent ce sujet au cours de quatre sessions :

  1. Qu’est-ce que le contrôle de l’asthme: qui, pourquoi et combien ?
  2. Améliorer le contrôle de l’asthme dans la communauté
  3. Traitement actuel standard de l’asthme
  4. Avantages et inconvénients de traitements d’appoint supplémentaires

Répondez au questionnaire d’évaluation et une heure sera ajoutée à votre DPC.

SPIRIVA® Respimat® est approuvée contre l’asthme dans l’Union Européenne, le Japon, les Etats-Unis et de nombreux autres pays. Les indications varient d’un pays à l’autre et les ressources pédagogiques peuvent contenir des informations sur des médicaments dont les indications ne sont pas approuvées dans votre pays.

,Área de aprendizagem sobre a asma sintomática

Este recurso educativo foi desenvolvido para profissionais de saúde na Europa envolvidos na prestação de cuidados a doentes asmáticos.

Sensibilização para a doença – Esta secção apresenta informações de referência relativas ao impacto da asma sintomática e a potenciais estratégias de gestão.

FMC acreditada pelo RCGP – No âmbito da atividade de formação médica contínua (FMC), pode tomar conhecimento das perspetivas dos médicos a respeito da gestão da asma sintomática na prática. Richard Russell e Thys van der Molen discutem em quatro sessões:

  1. Em que consiste o controlo da asma: quem, porquê e quantos?
  2. Melhorar o controlo da asma na comunidade
  3. Tratamento atual de referência para a asma
  4. Vantagens e desvantagens do tratamento complementar adicional

Ser-lhe-á creditada uma hora de DPC se responder com sucesso ao questionário de avaliação

O SPIRIVA® Respimat® está aprovado para utilização na asma na União Europeia, no Japão, nos EUA e em muitos outros países. A indicação varia em função do país e o recurso educativo poderá conter informação sobre medicamentos cujas indicações poderão não estar aprovadas no seu país.

,Zona de aprendizaje sobre el asma sintomática

Este recurso educativo ha sido elaborado por profesionales sanitarios de Europa que intervienen en la atención de pacientes con asma.

Concienciación sobre la enfermedad: Esta sección proporciona información general relativa al impacto del asma sintomática y a las posibles estrategias de tratamiento.

EMC homologada por el RCGP: Como parte de la actividad de educación médica continuada (EMC), puede aprender sobre las perspectivas de los médicos sobre el tratamiento del asma sintomática en la práctica clínica. Richard Russell y Thys van der Molen comentan en cuatro sesiones:

  1. Qué es el control del asma: ¿quién, por qué y cuántos?
  2. Mejorar el control del asma en el ámbito extrahospitalario
  3. Tratamiento de referencia actual para el asma
  4. Ventajas e inconvenientes del tratamiento complementario adicional

Se concederá una hora para la consecución de su crédito de DPP tras haber superado con éxito el cuestionario de evaluación.

SPIRIVA® Respimat® está autorizado para su uso en el asma en la Unión Europea, Japón, EE. UU. y muchos otros países. La indicación varía según el país y este recurso educativo puede contener información sobre medicamentos que no estén aprobados en su país para las indicaciones mencionadas.

,Spazio di apprendimento sull’asma sintomatico

Queste risorse didattiche sono state sviluppate per i professionisti del settore sanitario europei che operano nel campo dell’assistenza ai pazienti affetti da asma.

Sensibilizzazione – Questa sezione fornisce informazioni generali sugli effetti dell’asma sintomatica e sulle potenziali strategie di gestione.

CME accreditata dall'RCGP – All’interno delle attività di educazione medica continua (CME), puoi scoprire le prospettive mediche per la gestione pratica dell’asma sintomatica. Richard Russell e Thys van der Molen discutono in quattro sessioni di:

  1. Cos’è il controllo dell’asma: chi, perché e quanti?
  2. Migliorare il controllo dell’asma nella comunità
  3. L’attuale trattamento standard dell’asma
  4. Pro e contro dellla terapia aggiuntiva.

Il CPD (Sviluppo Professionale Continuo) ti sarà riconosciuto un’ora dopo, dietro superamento del questionario valutativo.

SPIRIVA® Respimat® è autorizzato per la cura dell’asma nell’Unione Europea, in Giappone, negli Stati Uniti e in molti altri Paesi. Le indicazioni variano da Paese a Paese e le risorse didattiche possono contenere informazioni su farmaci le cui indicazioni potrebbero non essere approvate nel tuo Paese.

,CSU Knowledge Centre and CME

The Chronic Spontaneous Urticaria (CSU) Knowledge Centre and CME has been developed to address the current lack of early diagnosis of this condition. Urticaria is more common than previously thought and studies suggest chronic urticaria affects up to 1% of the population at any given time with CSU responsible for two-thirds of these cases. 

Allergists, immunologists, dermatologists and other healthcare professionals involved in the management of CSU will find a range of content to support you in effectively diagnosing and treating the condition.

In the Knowledge Centre, you will find a disease overview, symposium highlights platform, video channel and additional resources including an events calendar and useful external links. 

This resource has been given a whole new look and feel, intended to improve accessibility and visual appeal. Recent content additions include case studies from urticaria experts Professor Christian Vestergaard and Professor Torsten Zuberbier and information on the TARGET My Hives app.

Also available within the CSU Knowledge Centre is an EACCME-accredited CME activity, 'Case Consults: Changing Paradigms in the Age of Biologics', available here. This activity is made up of three video presentations and two video case studies based on expert sessions from the Novartis-sponsored CSU symposium of the same name held at the 24th European Academy of Dermatology and Venereology (EADV) Congress 2015. Successful completion of this free activity earns you 1 CME credit.

,Symptomatic Asthma Learning Zone

This educational resource has been developed for healthcare professionals in Europe who are involved in the care of patients with asthma.

Disease Awareness - This section provides background information regarding the impact of symptomatic asthma and potential management strategies.

RCGP-accredited CME - Within the continuing medical education (CME) activity, you can learn about physician perspectives on managing symptomatic asthma in practice. Richard Russell and Thys van der Molen discuss in four sessions:

  1. What is asthma control: Who, why and how many?
  2. Improving asthma control in the community
  3. Current standard asthma treatment
  4. Pros and cons of additional add-on treatment.

One hour towards your CPD will be rewarded upon successful completion of the evaluation questionnaire

SPIRIVA® Respimat® is approved for use in asthma in the European Union, Japan, USA and many other countries. The indication varies by country and the educational resource may contain information about medications for which indications may not be approved in your country.

,

Psoriasis is a chronic inflammatory disease affecting approximately 2% of the world’s population. The Psoriasis Knowledge Centre provides dermatologists, family medicine doctors and other healthcare professionals with relevant information including epidemiology, pathophysiology, diagnosis and more.

A treatment section reviews the established treatments available for psoriasis and considers their modes of action, available clinical data and place in the therapeutic pathway.

Also located within the Psoriasis Knowledge Centre is a dedicated educational section focusing on IL-17A in Psoriasis. This free resource is intended to provide healthcare professionals with information on the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.

,IL-17A Header

Located within the Psoriasis Knowledge Centre, IL-17A in Psoriasis has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.

Content is arranged within multiple sections that are easy to navigate. Users can find expert videos, clinical slide decks on topics such as disease pathophysiology and emerging therapies, congress highlights, key publications and links to useful resources.

This free resource is intended for healthcare professionals involved in the treatment and management of patients with psoriasis.

This resource has been developed in collaboration with Novartis Pharma AG.

Clinical Case Studies

Animal Bite-related Infection

Infection: Skin and Skin Structure Infections

Marina Morgan, Consultant Medical Microbiologist
Royal Devon and Exeter Hospital, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK

Case History
A 73-year-old lady attended the emergency department nine hours after being bitten on the hand by a stray cat. She complained of severe pain in the wrist and the small puncture wounds seen near the wrist joint were reddened with accompanying lymphangitis and swelling.

Diabetic Foot Infection

Infection: Bone and Joint Infection

Paul Chadwick, Consultant Microbiologist, Salford Hospital, Salford Royal NHS Trust, Salford, UK

Case History
A 76-year-old male non-smoker with type 2 diabetes was admitted via the podiatry department. His right foot was red and swollen and a plain X-ray showed changes consistent with osteomyelitis, with destruction of the metatarsophalangeal joint of the great toe and lucencies within the soft tissues extending across the second, third and fourth toes.

Latest News

Blog

The 2003 British Thoracic Society and Scottish Intercollegiate Guidelines Network asthma management guidelines use the international consensus definition to describe asthma as:
“a chronic inflammatory disorder of the airways. In susceptible individuals inflammatory symptoms are usually associated with widespread but variable airflow obstruction and an increase in airway response to a variety of stimuli. Obstruction is often reversible either spontaneously or with treatment”.

During an asthma attack, also called an asthma exacerbation, airways become swollen and inflamed. The muscles around the airways contract narrowing the bronchial tubes.
Asthma attacks can be minor which improve with home treatment, or severe which can become a life threatening emergency.

This post discusses clinical assessment and treatment of patients with acute asthma exacerbations.

Medical Videos

An Animation Demonstrating the Role of Natural Killer Cells
An Animation Demonstrating the Role of Natural Killer Cells
An Animation of The Main Roles of the Immune System
An Animation of The Main Roles of the Immune System

Recent Drug Updates

Medical Journal Abstracts on Immunology

Psoriasis

-91 days ago -  Psoriasis

This review emphasizes the pathologic features of psoriatic lesions, recent genetic studies of psoriasis, and immunologic factors in the disease. The evolution of a psoriatic lesion entails a ...

Imatinib: a breakthrough of targeted therapy in cancer.

-19 days ago -  Imatinib: a breakthrough of targeted therapy in cancer.

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach ...

Medical Images

MRIs performed in a 37-year-old HIV+ patient
 MRIs performed in a 37-year-old HIV+ patient
MRI of the lumbarsacral spine
MRI of the lumbarsacral spine
Allergic Bronchopulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis
Pneumocystis jirovecii Pneumonia
Pneumocystis jirovecii Pneumonia
Abdominal X-ray
Abdominal X-ray
Acute Eosinophilic Pneumonia - radiograph
Acute Eosinophilic Pneumonia - radiograph
Hospital-acquired Pneumonia (HAP)
Hospital-acquired Pneumonia (HAP)
Key events leading up to the era of HAART
Key events leading up to the era of HAART
Metavir stage 3 (F3)
Metavir stage 3 (F3)

Clinical Guidelines

Myeloma: diagnosis and management

Feb 2016

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and..

... primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

This guideline includes recommendations on:
   - communication and support
   - laboratory investigations
   - imaging investigations
   - managing newly-diagnosed and relapsed myeloma
   - preventing and managing bone disease and other complications
   - monitoring

Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma

Nov 2015

The objective of this guideline is to provide healthcare professionals with guidance on the..

... investigation and management of patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). Individual patient circumstances may dictate an alternative approach. This is the first BCSH guideline on this topic and is in date at time of publication.

Clinical Trials

A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age

-1 days ago

The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate vaccine GSK1557484A, in children 6-35 months of ...

Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial (Hypogamma Int1)

-1 days ago

The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to eradicate rhinovirus in patients with primary hypogammaglobulinemia. Patients with hypogammaglobulinemia ...

Back to top